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Abstract
Background: About 40–50% of patients with familial microscopic hematuria (FMH) caused by thin basement
membrane nephropathy (TBMN) inherit heterozygous mutations in collagen IV genes (COL4A3, COL4A4). On long
follow-up, the full phenotypic spectrum of these patients varies a lot, ranging from isolated MH or MH plus low-
grade proteinuria to chronic renal failure of variable degree, including end-stage renal disease (ESRD).
Methods: Here, we performed Whole Exome Sequencing (WES) in patients of six families, presenting with
autosomal dominant FMH, with or without progression to proteinuria and loss of renal function, all previously
found negative for severe collagen IV mutations. Hierarchical filtering of the WES data was performed, followed by
mutation prediction analysis, Sanger sequencing and genetic segregation analysis.
Results: In one family with four patients, we found evidence for the contribution of two co-inherited variants in
two crucial genes expressed in the glomerular basement membrane (GBM); LAMA5-p.Pro1243Leu and COL4A5-p.
Asp654Tyr. Mutations in COL4A5 cause classical X-linked Alport Syndrome, while rare mutations in the LAMA5 have
been reported in patients with focal segmental glomerulosclerosis. The phenotypic spectrum of the patients
includes hematuria, proteinuria, focal segmental glomerulosclerosis, loss of kidney function and renal cortical cysts.
Conclusions: A modifier role of LAMA5 on the background of a hypomorphic Alport syndrome causing mutation is
a possible explanation of our findings. Digenic inheritance is another scenario, following the concept that
mutations at both loci more accurately explain the spectrum of symptoms, but further investigation is needed
under this concept. This is the third report linking a LAMA5 variant with human renal disease and expanding the
spectrum of genes involved in glomerular pathologies accompanied by familial hematurias. The cystic phenotype
overlaps with that of a mouse model, which carried a Lama5 hypomorphic mutation that caused severely reduced
Lama5 protein levels and produced kidney cysts.
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Background
Hereditary hematuric diseases comprise a genetically
and clinically heterogeneous group of conditions, a com-
mon feature of which is microscopic hematuria (MH)
since early childhood. The most frequent pathological
entity is thin basement membrane nephropathy (TBMN)
[1, 2], with an estimated population prevalence of 0.3–
1% [3, 4]. About 40–50% of familial TBMN are ex-
plained by heterozygous mutations in the COL4A3 and
COL4A4 genes, which encode for the α3 and α4 chains
of collagen IV, the most abundant component of GBM
[5]. A much more severe and progressive glomerulopa-
thy, which also presents with MH since childhood is
Alport syndrome, caused by either mutations in the
COL4A3/A4 genes or mutations in the X-linked
COL4A5 gene [2, 6]. Mutations in CFHR5, a gene play-
ing a role in the regulation of the alternative pathway of
complement, in FN1 (fibronectin 1), or in MYH9 (heavy
chain of myosin 9), comprise rarer genetic causes of her-
editary hematurias [1, 6–8].
Although TBMN, caused by COL4A mutations, was
considered for many years to be a benign condition ac-
companied by excellent prognosis on long follow-up,
several publications, including ours as early as 2007,
convincingly showed that this is not the case [9–11].
This is based on results showing that a variable subset of
patients will develop proteinuria and focal segmental
glomerulosclerosis (FSGS) and progress to chronic renal
failure, even end-stage renal disease (ESRD) [12]. In a
Cypriot cohort, up to 30% of TBMN patients with
known mutations reached ESRD, at an average age of
56-years. To date, these results have been verified by
multiple groups [13–17]. The exact mechanisms for this
adverse outcome remain unknown but the role of gen-
etic modifiers has been implicated [18–22]. A significant
feature of heterozygous COL4A mutations is the broad
phenotypic heterogeneity, while the clinical outcome is
at times better described as later-onset Alport-related
nephropathy (LOAN) [23]. Some authors also use the
diagnosis of autosomal dominant Alport syndrome.
Based on available data there must be more genes that
confer FMH when mutated [11, 24]. Whole-exome se-
quencing (WES) is one of the best modern genetic ap-
proaches for gene discovery. Here we report the analysis
of 6 families by (WES) and the finding of two variants
co-inherited in two genes, the COL4A5 and the LAMA5
genes. Invoking this digenic inheritance can better ex-
plain the spectrum of symptoms observed in some pa-
tients, than the variant at each one locus alone [25].
Methods
Six families segregating FMH in at least two generations
(autosomal dominant inheritance) were thoroughly stud-
ied. Some patients also had proteinuria, renal impairment
or ESRD. Renal biopsy showed FSGS and TBMN in two
of six families (Families CY5372 and CY5381). At first, the
index patient of each family underwent Next Generation
Sequencing (NGS) that included the parallel analysis of a
5-gene panel, COL4A3, COL4A4, COL4A5, CFHR5, FN1
(Ion Torrent, PGM, Life Sciences) [11]. Subsequently,
WES was performed in the index patients plus one unre-
lated healthy subject by Macrogen (Kyoto, Japan), using
the Illumina HiSeq platform (San Diego, CA, USA). The
analysis included all exons, splice junctions and 5’-UTR/
3’-UTR. Mean DNA fragment size was 101 bp. In total,
51.189.318 bases of genomic DNA were selected. The fil-
tering algorithm of the data (Fig. 1) gave special attention
to glomerulus specific genes [26]. Selected variants were
validated by Sanger DNA re-sequencing using the ABI
BigDye Terminator v1.1 Cycle Sequencing Kit and the
ABI PRISM 3130xl genetic analyzer.
The study was approved by the Cyprus National Bioeth-
ics Committee and all participants gave a signed consent.
Results
WES analysis
NGS analysis for the 5-gene panel was negative. In fam-
ily CY5500 (Table 1) a variant in the COL4A5 gene,
p.Asp654Tyr, was not considered as pathogenic and was
overlooked as it did not involve a conserved glycine
residue and was thought inadequate to explain the
phenotype. WES resulted to a mean of 9000 non-
synonymous SNPs and indels in coding regions, per in-
dividual (Additional file 1 After applying the analytical
filtering algorithm (Fig. 1), we excluded about ~ 8500
variants and ended with a list of 549 candidate variants.
When checked for any relation with the glomerular
function, for animal models, or functional studies
available in the literature, seven variants were considered
of high risk, confirmed by Sanger re-sequencing
(Tables 2 and 3). Two variants were predicted by five of
six software to be damaging/disease causing. Specifically,
variant COL4A5-p.Asp654Tyr was not found in 54 sam-
ples of the Cypriot general population nor in 305 sam-
ples with FMH tested at our setting. Also this variant
was never reported in the ExAC genomes database [27].
Variant LAMA5-p.Pro1243Leu was neither found in 81
healthy individuals of the Cypriot general population nor
was it present in any of 159 TBMN patients’ DNA. Also,
according to the ExAC genomes database, it was found
in European (non-Finish) populations with a frequency
of ~ 1/21,123.
Family CY5500
Both variants on LAMA5 and COL4A5 genes are co-
inherited by all four patients in family CY5500. The
LAMA5 variant has been inherited by male UCY2067
that he is presently healthy. There is oral information
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that the grandfather (generation I) was suffering by
chronic kidney disease. Below there is analytical clinical de-
scription for all mutation carriers of family CY5500 (Fig. 2).
UCY2069
CA is a 57-yr-old male, diagnosed with, and treated for,
hypertension at the age of 36-yrs, associated with MH,
minimal proteinuria and impaired renal function
(MDRD eGFR = 66.0 ml/min/1.73m2). At the age of 54-
yrs he developed heavy proteinuria of nephrotic range.
Despite treatment with steroids and cyclosporine, his
kidney function deteriorated and he developed ESRD at
the age of 57-yrs. At the age of 54-yrs he had a kidney
biopsy showing FSGS. The GBM was folded and appeared
thick in many areas, while the podocytes appeared vacuo-
lated and with marked fusion. Renal ultrasound showed
multiple renal cortical cysts bilaterally, well before he
reached ESRD (Fig. 3).
UCY4041
SCA, the daughter of patient CA, is a 25-yr-old girl with
MH, borderline proteinuria, normal blood pressure and
normal renal function (MDRD eGFR = 130 ml/min/
1.73m2). A recent kidney biopsy showed FSGS. Mean
Fig. 1 Hierarchical filtering that we followed for mining the Whole Exome Sequencing data
Table 1 Clinical data of CY5500 family
Patient Gender Micr. Hematuria Proteinuria CRF Kidney Cysts ESRD Renal biopsy result (age range performed)
UCY2069 Male YES YES YES YES YES, dialysis FSGS – thick GBM (50–55 yrs)
UCY2075 Male YES YES YES YES YES, transplanted FSGS - no EM (50–55 yrs)
UCY2074 Female YES YES NO Not known NO FSGS (20–25 yrs)
UCY4041 Female YES YES NO NO NO FSGS – thinning and thickening of GBM (25–30 yrs)
CRF Chronic Renal Failure, ESRD End Stage of Renal Disease, EM Electron Microscope, FSGS Focal Segmental Glomerulosclerosis, GBM Glomerular
Basement Membrane
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width of the GBM was 218.73 nm, thinner than normal.
Two measurements showed thickening alternating with
thinning. In the most part the podocyte processes were
maintained normal but there were a few segments with
effacement. Folding of the GBM was observed in a per-
centage of 5% and in two areas thickening was observed.
There were no clear pathognomonic features for Alport
syndrome. Electron microscopy showed some deposits
which most probably were IgM precipitates, recognized
by immunofluorescent microscopy, localized in the per-
iphery and the mesangium. Renal ultrasound was nega-
tive for renal cysts.
UCY2075
Male patient SA, brother of CA, aged 60-yrs, was diag-
nosed with heavy proteinuria, in the nephrotic range, as-
sociated with MH and renal impairment (MDRD
eGFR = 43.0 ml/min/1.73m2) at the age of 51-yrs. At age
57-yrs he developed ESRD and had a cadaveric kidney
transplantation. At the age of 51-yrs he had a kidney bi-
opsy that revealed secondary FSGS, which at the time
was attributed to pre-existing arterial hypertension and
renal function impairment due to proteinuria. Electron
microscope analysis is not available. Renal ultrasound
showed multiple renal cortical cysts.
UCY2074
CSA, the daughter of patient SA, is a 34-yr-old girl, with
MH and proteinuria. Her kidney function was normal at
the age of 29-yrs, taking corticosteroids therapy (MDRD
eGFR = 118.0 ml/min/1.73m2). She had a kidney biopsy
at the age of 24-yrs, due to MH and proteinuria, reveal-
ing FSGS. Renal ultrasound was not available.
UCY2067
EA, the son of CA, aged 27, has inherited only the vari-
ant LAMA5-p.Pro1243Leu, and he is presently healthy.
Discussion
Miner et al. [28] described Lama5 (laminin alpha 5
chain) in 1995, member of the vertebrate subfamily of
laminin chains, widely expressed in adult tissues, with
highest levels in lung, heart, and kidney. In mature
glomeruli, collagen α1α2α1(IV) and laminin α1β1γ1
(LN-111) interacting networks are replaced by collagen
Table 3 Direct DNA re-sequencing results (AD: autosomal dominant). Variants not following AD inheritance have not been studied
further
Family Gene Variant WES result confirmed? Ref. codon New codon Family analysis Inheritance pattern
compatible with AD
General population
analysis
CY5500 LAMA5 p.P1243L YES CCG CTG YES YES 0/81
0/159a
COL4A5 p.D654Y YES GAT TAT YES YES 0/54
0/305a
CY5372 LAMB2 p.S1361 W YES TCG TGG YES NO –
CY5381 MMP24 p.G119R YES GGG GGA YES More samples needed 0/54
CY5394 SYNPO2L p.R158H YES CGC CTG YES More samples needed –
NID1 p.V937 M YES GTG GTA YES NO –
CY5417 TJP1 p.R143Q YES CGG CAG YES NO –
aResults from patients’ cohorts tested in our lab
Fig. 2 Pedigree of family CY5500. For family members with a UCY code, there is available a DNA sample. Four patients of the family carry both
variants (patients UCY2075 and UCY2069 are actually hemizygous for the COL4A5 variant). Family member UCY2067 carries only the LAMA5
variant in heterozygosity, having normal kidney function and being negative for microscopic hematuria, aged 27
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α3α4α5(IV), laminin α5β1γ1 (LN-511), and laminin
α5β2γ1 (LN-521), as glomerular capillary loops expand
[29]. It is documented that the maintenance of glomeru-
lar filtration barrier integrity requires laminin alpha5
[30]. Despite the fact that Lama5 mouse knockouts are
fatal [31], mice with a hypomorphic Lama5 mutation
(Lama5neo) that reduces laminin α5 expression, exhibit
proteinuria, hematuria and cystic kidneys [32]. Podocyte-
specific inactivation of Lama5 in mice, resulted in varying
degrees of proteinuria and rates of progression to neph-
rotic syndrome. The GBM of the proteinuric mice ap-
peared thickened and “moth-eaten,” and podocyte foot
processes were effaced [30]. These facts, added to the
population data mentioned above, enhance the likelihood
that DNA variant LAMA5-p.Pro1243Leu is a mutation,
probably a hypomorphic one, since the patients we identi-
fied exhibit a great phenotypic similarity with these animal
models, presenting with hematuria, proteinuria, renal im-
pairment, thinning and thickening of the GBM, podocyte
foot processes effacement and multiple renal cysts.
In the absence of proper functional experiments it is im-
possible to know how exactly this Lama5 variant affects
GBM structure and integrity. We can speculate however
that the interaction of the laminin network with the colla-
gen IV α3α4α5 network might be disturbed, resulting in
distortion of the mature GBM meshwork and the glom-
erular filtration barrier. It is also reasonable to suspect an
additive effect regarding the damage of GBM in the pres-
ence of a defective alpha 5 (Col-IV) chain, where if a dos-
age threshold is exceeded then a pathogenic phenotype
appears. Even though analytical functional experiments
are beyond the scope of this paper, we propose that the
phenotype is better described by taking into consideration
the variants at both loci than each one on its own [25].
It is equally worth mentioning that this is the third re-
port presenting data supporting a probable contribution
of the LAMA5 gene to human disease. In a previous
report the authors found novel LAMA5 mutations, pre-
dicted to be deleterious, in three out of five patients with
FSGS or presumed FSGS, also co-inherited with muta-
tions in other genes [33]. Similar results were reported
by another study [13]. No renal cysts were described in
those patients. An additional argument in support of our
hypothesis is the fact that laminin alpha 5 is an import-
ant protein of the glomerulus and an interacting partner
of collagen IV, while animal models and patients exhibit
similar phenotypes with our patients. While the evidence
presented is valid, more studies are needed and more pa-
tients must be studied before this link is unequivocally
documented. Probably, the easiest way is screening for
mutations or for modifier variants in the LAMA5 gene
in multiple FMH and Alport syndrome families. Confirm-
ation of these results will be of high clinical importance,
expanding the spectrum of genes involved in glomerular
pathologies. Finally, in recent years other examples have
been reported of patients with COL4A5 mutations and
Alport syndrome, and phenotypes exacerbated by co-
inheritance of mutations in other genes. These include
mutations in other collagen IV genes (COL4A3/A4) and in
the MYO1E gene [34, 35]. It should not escape our atten-
tion that high throughput analysis, including NGS technolo-
gies are enabling us to detect and connect clearly pathogenic
or hypomorphic mutations in different genes and thus eluci-
dating previously complex phenotypes. Often times though,
it is difficult to discriminate cases of true non-Mendelian
digenic inheritance from monogenic Mendelian inheritance
of phenotypes exacerbated by serendipitous co-inheriting of a
second non-allelic mutation or from the effect of otherwise
neutral genetic modifiers, or even from the serendipitous co-
inheritance of two independent clinical entities.
Conclusions
In conclusion, we found evidence that digenic inherit-
ance in patients of one family presenting with FMH,
Fig. 3 Ultra-sound of the kidneys of patient CA (UCY2069 on Fig. 1), aged 57-yrs, presently on ESRD. Both Kidneys are smaller than normal, measuring
Rt kidney 8.88 cm in long diameter and the Lt kidney 9.51 cm, with increased echogenicity and cortical thinning, cortex measuring about 0.88 cm.
There is no polycystic kidney disease (pelvocalyceal dilatation). Multiple cortical cysts are noted in both kidneys, about 6–8 cysts in each kidney, the
bigger to the Rt about 4.5 cm and to the Lt about 3.6 cm. The cysts however have been present at least since 4-yrs, according to the patient’s medical
record, at the time his renal function was much better (MDRD 50 ml/min)
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renal failure/ESRD, FSGS and cystic kidneys, can more
clearly explain the phenotypic spectrum than one gene
alone. The suspected genes are COL4A5 and LAMA5.
Existing animal models and two previous reports for rare
mutations in LAMA5 gene support this observation.
These results need further confirmation, as LAMA5 could
explain a percentage of patients with complex phenotypes.
Additional file
Additional file 1: WES statistics. Number of genetic variants called after
the WES analysis. (DOCX 15 kb)
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